EGFR and non-small cell lung carcinoma: Activation of EGFR has been reported to establish an immunosuppressive TME in NSCLC cells, including promotion of suppressive TAMs, Tregs, blockade of T cell infiltration and cytotoxicity, and induction of inhibitory cytokines, which impair the immunotherapy (Lin et al., 2019).